Less than 18 months since submitting the first part of a modular PMA, the VenaSeal varicose vein treatment system has now gained FDA PMA approval
Medtronic plc says that it has successfully completed the previously announced acquisition of Covidien plc
Covidien plc has gained CE Mark approval for its Stellarex™ drug-coated angioplasty balloon which will be sold to Spectranetics when the Medtronic deal goes through.
Innovative design of wireless, vitamin-sized capsule recognized for its profound impact on improving the standard-of-care for small bowel examinations
Covidien plc has gained U.S. FDA 510(k) clearance for its Fortrex™ over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter.
CE Mark approval for Nellcor™ PM100N Bedside SpO2 Patient Monitoring System brings the latest in bedside pulse oximetry to the home healthcare.
Covidien’s acquisition of Sapheon this summer is looking like a smart move as pivotal clinical study results at 6 months suggest it successfully treats symptomatic varicose veins.
Covidien says the HawkOne™ System strengthens its directional atherectomy platform with a versatile solution for the treatment of peripheral arterial disease.
Spectranetics is to acquire Covidien’s Stellarex™ drug coated angioplasty balloon platform in a move that is likely to be part of the plan to meet anti-trust conditions related to next year’s takeover by Medtronic.
Covidien’s updated software features a more intuitive interface that helps reduce planning time and enhances airway visualization.
Covidien supports publicity initiative to drive earlier diagnosis of lung cancer, opening up treatment options and improved patient outcomes
A new injunction issued by a US district court, prevents Ethicon from manufacturing, marketing and selling the Harmonic ACE®+7.
Covidien’s newly cleared Nellcor™ Portable SpO2 Patient Monitoring System (PM10N) system is the only commercially available portable oximeter that is equipped with home care and sleep study modes.
Covidien plc says its Sonicision™ Cordless Ultrasonic Dissection Device portfolio extends to 13 cm, 26 cm, and 48 cm device lengths following U.S. FDA 510(k) clearance.
Covidien has announced the start of enrollment in two clinical trials that it says further underscores the safety and effectiveness of the company’s advanced neurovascular solutions.
Sales ramped 4% compared with the equivalent period a year ago, but an increase in estimates of costs from pelvic mesh products liability cases saw S,G&A expenses ramp.